nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefdinir—MPO—urinary bladder cancer	0.566	1	CbGaD
Cefdinir—MPO—Carboplatin—urinary bladder cancer	0.169	0.539	CbGbCtD
Cefdinir—MPO—Cisplatin—urinary bladder cancer	0.144	0.461	CbGbCtD
Cefdinir—SLC15A1—epithelium—urinary bladder cancer	0.00122	0.0835	CbGeAlD
Cefdinir—SLC15A1—renal system—urinary bladder cancer	0.00113	0.0775	CbGeAlD
Cefdinir—MPO—epithelium—urinary bladder cancer	0.00109	0.0752	CbGeAlD
Cefdinir—SLC15A2—prostate gland—urinary bladder cancer	0.00103	0.0711	CbGeAlD
Cefdinir—MPO—renal system—urinary bladder cancer	0.00101	0.0697	CbGeAlD
Cefdinir—SLC22A5—prostate gland—urinary bladder cancer	0.000899	0.0618	CbGeAlD
Cefdinir—SLC15A2—seminal vesicle—urinary bladder cancer	0.000874	0.0601	CbGeAlD
Cefdinir—SLC15A1—vagina—urinary bladder cancer	0.000816	0.0561	CbGeAlD
Cefdinir—SLC22A5—seminal vesicle—urinary bladder cancer	0.000761	0.0523	CbGeAlD
Cefdinir—SLC15A2—renal system—urinary bladder cancer	0.000705	0.0484	CbGeAlD
Cefdinir—SLC15A2—urethra—urinary bladder cancer	0.000692	0.0476	CbGeAlD
Cefdinir—SLC22A5—renal system—urinary bladder cancer	0.000613	0.0421	CbGeAlD
Cefdinir—SLC22A5—urethra—urinary bladder cancer	0.000602	0.0414	CbGeAlD
Cefdinir—SLC15A2—female reproductive system—urinary bladder cancer	0.000564	0.0388	CbGeAlD
Cefdinir—SLC15A2—vagina—urinary bladder cancer	0.00051	0.0351	CbGeAlD
Cefdinir—SLC22A5—female reproductive system—urinary bladder cancer	0.000491	0.0337	CbGeAlD
Cefdinir—MPO—lymph node—urinary bladder cancer	0.000475	0.0327	CbGeAlD
Cefdinir—SLC22A5—vagina—urinary bladder cancer	0.000444	0.0305	CbGeAlD
Cefdinir—SLC15A2—lymph node—urinary bladder cancer	0.00033	0.0227	CbGeAlD
Cefdinir—SLC22A5—lymph node—urinary bladder cancer	0.000287	0.0197	CbGeAlD
Cefdinir—Anorexia—Thiotepa—urinary bladder cancer	0.000213	0.002	CcSEcCtD
Cefdinir—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.000212	0.00199	CcSEcCtD
Cefdinir—Renal failure acute—Methotrexate—urinary bladder cancer	0.000212	0.00199	CcSEcCtD
Cefdinir—Flatulence—Cisplatin—urinary bladder cancer	0.000211	0.00198	CcSEcCtD
Cefdinir—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000209	0.00196	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.000207	0.00194	CcSEcCtD
Cefdinir—Leukopenia—Gemcitabine—urinary bladder cancer	0.000206	0.00193	CcSEcCtD
Cefdinir—Hepatic failure—Epirubicin—urinary bladder cancer	0.000204	0.00191	CcSEcCtD
Cefdinir—Leukopenia—Fluorouracil—urinary bladder cancer	0.000203	0.0019	CcSEcCtD
Cefdinir—Hypertension—Gemcitabine—urinary bladder cancer	0.000199	0.00186	CcSEcCtD
Cefdinir—Somnolence—Thiotepa—urinary bladder cancer	0.000199	0.00186	CcSEcCtD
Cefdinir—Renal failure acute—Epirubicin—urinary bladder cancer	0.000198	0.00186	CcSEcCtD
Cefdinir—Dyspepsia—Thiotepa—urinary bladder cancer	0.000197	0.00184	CcSEcCtD
Cefdinir—Convulsion—Fluorouracil—urinary bladder cancer	0.000196	0.00184	CcSEcCtD
Cefdinir—Chest pain—Gemcitabine—urinary bladder cancer	0.000196	0.00184	CcSEcCtD
Cefdinir—Decreased appetite—Thiotepa—urinary bladder cancer	0.000194	0.00182	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000194	0.00182	CcSEcCtD
Cefdinir—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.000194	0.00182	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000193	0.00181	CcSEcCtD
Cefdinir—Chest pain—Fluorouracil—urinary bladder cancer	0.000193	0.00181	CcSEcCtD
Cefdinir—Renal impairment—Epirubicin—urinary bladder cancer	0.000192	0.0018	CcSEcCtD
Cefdinir—Leukopenia—Cisplatin—urinary bladder cancer	0.000192	0.0018	CcSEcCtD
Cefdinir—Constipation—Thiotepa—urinary bladder cancer	0.000191	0.00179	CcSEcCtD
Cefdinir—Purpura—Epirubicin—urinary bladder cancer	0.00019	0.00178	CcSEcCtD
Cefdinir—Hepatic failure—Doxorubicin—urinary bladder cancer	0.000188	0.00177	CcSEcCtD
Cefdinir—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000188	0.00176	CcSEcCtD
Cefdinir—Cardiac failure—Epirubicin—urinary bladder cancer	0.000188	0.00176	CcSEcCtD
Cefdinir—Convulsion—Cisplatin—urinary bladder cancer	0.000186	0.00174	CcSEcCtD
Cefdinir—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000185	0.00173	CcSEcCtD
Cefdinir—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000184	0.00173	CcSEcCtD
Cefdinir—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000183	0.00172	CcSEcCtD
Cefdinir—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000183	0.00171	CcSEcCtD
Cefdinir—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000181	0.0017	CcSEcCtD
Cefdinir—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.000179	0.00168	CcSEcCtD
Cefdinir—Anorexia—Gemcitabine—urinary bladder cancer	0.000179	0.00168	CcSEcCtD
Cefdinir—Renal impairment—Doxorubicin—urinary bladder cancer	0.000178	0.00167	CcSEcCtD
Cefdinir—Abdominal pain—Thiotepa—urinary bladder cancer	0.000177	0.00166	CcSEcCtD
Cefdinir—Body temperature increased—Thiotepa—urinary bladder cancer	0.000177	0.00166	CcSEcCtD
Cefdinir—Anorexia—Fluorouracil—urinary bladder cancer	0.000176	0.00165	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.000176	0.00165	CcSEcCtD
Cefdinir—Leukopenia—Etoposide—urinary bladder cancer	0.000176	0.00165	CcSEcCtD
Cefdinir—Purpura—Doxorubicin—urinary bladder cancer	0.000176	0.00165	CcSEcCtD
Cefdinir—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000175	0.00164	CcSEcCtD
Cefdinir—Cardiac failure—Doxorubicin—urinary bladder cancer	0.000174	0.00163	CcSEcCtD
Cefdinir—Loss of consciousness—Etoposide—urinary bladder cancer	0.000173	0.00162	CcSEcCtD
Cefdinir—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000171	0.00161	CcSEcCtD
Cefdinir—Convulsion—Etoposide—urinary bladder cancer	0.00017	0.0016	CcSEcCtD
Cefdinir—Insomnia—Gemcitabine—urinary bladder cancer	0.00017	0.00159	CcSEcCtD
Cefdinir—Hypertension—Etoposide—urinary bladder cancer	0.00017	0.00159	CcSEcCtD
Cefdinir—Asthma—Methotrexate—urinary bladder cancer	0.000169	0.00159	CcSEcCtD
Cefdinir—Chest pain—Etoposide—urinary bladder cancer	0.000167	0.00157	CcSEcCtD
Cefdinir—Insomnia—Fluorouracil—urinary bladder cancer	0.000167	0.00157	CcSEcCtD
Cefdinir—Somnolence—Gemcitabine—urinary bladder cancer	0.000167	0.00157	CcSEcCtD
Cefdinir—Anorexia—Cisplatin—urinary bladder cancer	0.000167	0.00157	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000165	0.00155	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000165	0.00155	CcSEcCtD
Cefdinir—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000165	0.00154	CcSEcCtD
Cefdinir—Somnolence—Fluorouracil—urinary bladder cancer	0.000164	0.00154	CcSEcCtD
Cefdinir—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000163	0.00153	CcSEcCtD
Cefdinir—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000163	0.00153	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000162	0.00152	CcSEcCtD
Cefdinir—Constipation—Gemcitabine—urinary bladder cancer	0.000161	0.00151	CcSEcCtD
Cefdinir—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000161	0.00151	CcSEcCtD
Cefdinir—Pancytopenia—Methotrexate—urinary bladder cancer	0.000161	0.00151	CcSEcCtD
Cefdinir—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00016	0.00151	CcSEcCtD
Cefdinir—Asthenia—Thiotepa—urinary bladder cancer	0.00016	0.0015	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00016	0.0015	CcSEcCtD
Cefdinir—Asthma—Epirubicin—urinary bladder cancer	0.000158	0.00148	CcSEcCtD
Cefdinir—Neutropenia—Methotrexate—urinary bladder cancer	0.000158	0.00148	CcSEcCtD
Cefdinir—Pruritus—Thiotepa—urinary bladder cancer	0.000158	0.00148	CcSEcCtD
Cefdinir—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000157	0.00147	CcSEcCtD
Cefdinir—Anorexia—Etoposide—urinary bladder cancer	0.000153	0.00143	CcSEcCtD
Cefdinir—Diarrhoea—Thiotepa—urinary bladder cancer	0.000153	0.00143	CcSEcCtD
Cefdinir—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000152	0.00143	CcSEcCtD
Cefdinir—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000152	0.00143	CcSEcCtD
Cefdinir—Decreased appetite—Cisplatin—urinary bladder cancer	0.000152	0.00143	CcSEcCtD
Cefdinir—Pneumonia—Methotrexate—urinary bladder cancer	0.000152	0.00142	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000151	0.00142	CcSEcCtD
Cefdinir—Pancytopenia—Epirubicin—urinary bladder cancer	0.00015	0.00141	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000149	0.0014	CcSEcCtD
Cefdinir—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000149	0.00139	CcSEcCtD
Cefdinir—Renal failure—Methotrexate—urinary bladder cancer	0.000148	0.00139	CcSEcCtD
Cefdinir—Neutropenia—Epirubicin—urinary bladder cancer	0.000148	0.00139	CcSEcCtD
Cefdinir—Dizziness—Thiotepa—urinary bladder cancer	0.000148	0.00139	CcSEcCtD
Cefdinir—Stomatitis—Methotrexate—urinary bladder cancer	0.000147	0.00138	CcSEcCtD
Cefdinir—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000146	0.00137	CcSEcCtD
Cefdinir—Asthma—Doxorubicin—urinary bladder cancer	0.000146	0.00137	CcSEcCtD
Cefdinir—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000146	0.00137	CcSEcCtD
Cefdinir—Haematuria—Methotrexate—urinary bladder cancer	0.000144	0.00135	CcSEcCtD
Cefdinir—Somnolence—Etoposide—urinary bladder cancer	0.000143	0.00134	CcSEcCtD
Cefdinir—Vomiting—Thiotepa—urinary bladder cancer	0.000142	0.00133	CcSEcCtD
Cefdinir—Pneumonia—Epirubicin—urinary bladder cancer	0.000142	0.00133	CcSEcCtD
Cefdinir—Rash—Thiotepa—urinary bladder cancer	0.000141	0.00132	CcSEcCtD
Cefdinir—Dermatitis—Thiotepa—urinary bladder cancer	0.000141	0.00132	CcSEcCtD
Cefdinir—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000141	0.00132	CcSEcCtD
Cefdinir—Headache—Thiotepa—urinary bladder cancer	0.00014	0.00131	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00014	0.00131	CcSEcCtD
Cefdinir—Decreased appetite—Etoposide—urinary bladder cancer	0.000139	0.00131	CcSEcCtD
Cefdinir—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000139	0.0013	CcSEcCtD
Cefdinir—Renal failure—Epirubicin—urinary bladder cancer	0.000139	0.0013	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000139	0.0013	CcSEcCtD
Cefdinir—Body temperature increased—Cisplatin—urinary bladder cancer	0.000138	0.0013	CcSEcCtD
Cefdinir—Stomatitis—Epirubicin—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Cefdinir—Jaundice—Epirubicin—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Cefdinir—Constipation—Etoposide—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Cefdinir—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000137	0.00129	CcSEcCtD
Cefdinir—Neutropenia—Doxorubicin—urinary bladder cancer	0.000137	0.00128	CcSEcCtD
Cefdinir—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000136	0.00128	CcSEcCtD
Cefdinir—Haemoglobin—Methotrexate—urinary bladder cancer	0.000136	0.00128	CcSEcCtD
Cefdinir—Haemorrhage—Methotrexate—urinary bladder cancer	0.000135	0.00127	CcSEcCtD
Cefdinir—Asthenia—Gemcitabine—urinary bladder cancer	0.000135	0.00126	CcSEcCtD
Cefdinir—Haematuria—Epirubicin—urinary bladder cancer	0.000134	0.00126	CcSEcCtD
Cefdinir—Pruritus—Gemcitabine—urinary bladder cancer	0.000133	0.00125	CcSEcCtD
Cefdinir—Nausea—Thiotepa—urinary bladder cancer	0.000133	0.00124	CcSEcCtD
Cefdinir—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000132	0.00123	CcSEcCtD
Cefdinir—Pneumonia—Doxorubicin—urinary bladder cancer	0.000131	0.00123	CcSEcCtD
Cefdinir—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000131	0.00123	CcSEcCtD
Cefdinir—Pruritus—Fluorouracil—urinary bladder cancer	0.000131	0.00123	CcSEcCtD
Cefdinir—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000129	0.00121	CcSEcCtD
Cefdinir—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000129	0.00121	CcSEcCtD
Cefdinir—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000129	0.00121	CcSEcCtD
Cefdinir—Renal failure—Doxorubicin—urinary bladder cancer	0.000128	0.0012	CcSEcCtD
Cefdinir—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000128	0.0012	CcSEcCtD
Cefdinir—Haemoglobin—Epirubicin—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Stomatitis—Doxorubicin—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Jaundice—Doxorubicin—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Abdominal pain—Etoposide—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Body temperature increased—Etoposide—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Haemorrhage—Epirubicin—urinary bladder cancer	0.000127	0.00119	CcSEcCtD
Cefdinir—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000126	0.00119	CcSEcCtD
Cefdinir—Asthenia—Cisplatin—urinary bladder cancer	0.000126	0.00118	CcSEcCtD
Cefdinir—Haematuria—Doxorubicin—urinary bladder cancer	0.000124	0.00117	CcSEcCtD
Cefdinir—Dizziness—Fluorouracil—urinary bladder cancer	0.000122	0.00115	CcSEcCtD
Cefdinir—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000122	0.00114	CcSEcCtD
Cefdinir—Diarrhoea—Cisplatin—urinary bladder cancer	0.00012	0.00112	CcSEcCtD
Cefdinir—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00012	0.00112	CcSEcCtD
Cefdinir—Vomiting—Gemcitabine—urinary bladder cancer	0.000119	0.00112	CcSEcCtD
Cefdinir—Rash—Gemcitabine—urinary bladder cancer	0.000118	0.00111	CcSEcCtD
Cefdinir—Dermatitis—Gemcitabine—urinary bladder cancer	0.000118	0.00111	CcSEcCtD
Cefdinir—Hypersensitivity—Etoposide—urinary bladder cancer	0.000118	0.00111	CcSEcCtD
Cefdinir—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000118	0.0011	CcSEcCtD
Cefdinir—Headache—Gemcitabine—urinary bladder cancer	0.000118	0.0011	CcSEcCtD
Cefdinir—Vomiting—Fluorouracil—urinary bladder cancer	0.000117	0.0011	CcSEcCtD
Cefdinir—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000117	0.0011	CcSEcCtD
Cefdinir—Rash—Fluorouracil—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Cefdinir—Dermatitis—Fluorouracil—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Cefdinir—Headache—Fluorouracil—urinary bladder cancer	0.000116	0.00109	CcSEcCtD
Cefdinir—Asthenia—Etoposide—urinary bladder cancer	0.000115	0.00108	CcSEcCtD
Cefdinir—Pruritus—Etoposide—urinary bladder cancer	0.000114	0.00106	CcSEcCtD
Cefdinir—Nausea—Gemcitabine—urinary bladder cancer	0.000112	0.00105	CcSEcCtD
Cefdinir—Vomiting—Cisplatin—urinary bladder cancer	0.000111	0.00104	CcSEcCtD
Cefdinir—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000111	0.00104	CcSEcCtD
Cefdinir—Rash—Cisplatin—urinary bladder cancer	0.00011	0.00104	CcSEcCtD
Cefdinir—Dermatitis—Cisplatin—urinary bladder cancer	0.00011	0.00103	CcSEcCtD
Cefdinir—Diarrhoea—Etoposide—urinary bladder cancer	0.00011	0.00103	CcSEcCtD
Cefdinir—Nausea—Fluorouracil—urinary bladder cancer	0.00011	0.00103	CcSEcCtD
Cefdinir—Flatulence—Epirubicin—urinary bladder cancer	0.000109	0.00102	CcSEcCtD
Cefdinir—Dizziness—Etoposide—urinary bladder cancer	0.000106	0.000995	CcSEcCtD
Cefdinir—Leukopenia—Methotrexate—urinary bladder cancer	0.000105	0.000989	CcSEcCtD
Cefdinir—Nausea—Cisplatin—urinary bladder cancer	0.000104	0.000976	CcSEcCtD
Cefdinir—Convulsion—Methotrexate—urinary bladder cancer	0.000102	0.000957	CcSEcCtD
Cefdinir—Vomiting—Etoposide—urinary bladder cancer	0.000102	0.000957	CcSEcCtD
Cefdinir—Agitation—Epirubicin—urinary bladder cancer	0.000101	0.00095	CcSEcCtD
Cefdinir—Rash—Etoposide—urinary bladder cancer	0.000101	0.000949	CcSEcCtD
Cefdinir—Dermatitis—Etoposide—urinary bladder cancer	0.000101	0.000948	CcSEcCtD
Cefdinir—Headache—Etoposide—urinary bladder cancer	0.000101	0.000943	CcSEcCtD
Cefdinir—Flatulence—Doxorubicin—urinary bladder cancer	0.0001	0.000943	CcSEcCtD
Cefdinir—Chest pain—Methotrexate—urinary bladder cancer	0.0001	0.00094	CcSEcCtD
Cefdinir—Leukopenia—Epirubicin—urinary bladder cancer	9.87e-05	0.000925	CcSEcCtD
Cefdinir—Loss of consciousness—Epirubicin—urinary bladder cancer	9.69e-05	0.000909	CcSEcCtD
Cefdinir—Anaphylactic shock—Methotrexate—urinary bladder cancer	9.61e-05	0.000902	CcSEcCtD
Cefdinir—Convulsion—Epirubicin—urinary bladder cancer	9.55e-05	0.000896	CcSEcCtD
Cefdinir—Nausea—Etoposide—urinary bladder cancer	9.53e-05	0.000894	CcSEcCtD
Cefdinir—Hypertension—Epirubicin—urinary bladder cancer	9.52e-05	0.000893	CcSEcCtD
Cefdinir—Thrombocytopenia—Methotrexate—urinary bladder cancer	9.41e-05	0.000883	CcSEcCtD
Cefdinir—Chest pain—Epirubicin—urinary bladder cancer	9.38e-05	0.00088	CcSEcCtD
Cefdinir—Agitation—Doxorubicin—urinary bladder cancer	9.37e-05	0.000879	CcSEcCtD
Cefdinir—Dry mouth—Epirubicin—urinary bladder cancer	9.18e-05	0.000861	CcSEcCtD
Cefdinir—Anorexia—Methotrexate—urinary bladder cancer	9.16e-05	0.000859	CcSEcCtD
Cefdinir—Leukopenia—Doxorubicin—urinary bladder cancer	9.13e-05	0.000856	CcSEcCtD
Cefdinir—Anaphylactic shock—Epirubicin—urinary bladder cancer	9e-05	0.000844	CcSEcCtD
Cefdinir—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.96e-05	0.000841	CcSEcCtD
Cefdinir—Shock—Epirubicin—urinary bladder cancer	8.85e-05	0.00083	CcSEcCtD
Cefdinir—Convulsion—Doxorubicin—urinary bladder cancer	8.84e-05	0.000829	CcSEcCtD
Cefdinir—Thrombocytopenia—Epirubicin—urinary bladder cancer	8.81e-05	0.000826	CcSEcCtD
Cefdinir—Hypertension—Doxorubicin—urinary bladder cancer	8.8e-05	0.000826	CcSEcCtD
Cefdinir—Insomnia—Methotrexate—urinary bladder cancer	8.69e-05	0.000815	CcSEcCtD
Cefdinir—Chest pain—Doxorubicin—urinary bladder cancer	8.68e-05	0.000814	CcSEcCtD
Cefdinir—Anorexia—Epirubicin—urinary bladder cancer	8.57e-05	0.000804	CcSEcCtD
Cefdinir—Somnolence—Methotrexate—urinary bladder cancer	8.54e-05	0.000801	CcSEcCtD
Cefdinir—Dry mouth—Doxorubicin—urinary bladder cancer	8.49e-05	0.000796	CcSEcCtD
Cefdinir—Dyspepsia—Methotrexate—urinary bladder cancer	8.46e-05	0.000794	CcSEcCtD
Cefdinir—Decreased appetite—Methotrexate—urinary bladder cancer	8.36e-05	0.000784	CcSEcCtD
Cefdinir—Anaphylactic shock—Doxorubicin—urinary bladder cancer	8.32e-05	0.000781	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	8.3e-05	0.000778	CcSEcCtD
Cefdinir—Shock—Doxorubicin—urinary bladder cancer	8.19e-05	0.000768	CcSEcCtD
Cefdinir—Thrombocytopenia—Doxorubicin—urinary bladder cancer	8.15e-05	0.000764	CcSEcCtD
Cefdinir—Insomnia—Epirubicin—urinary bladder cancer	8.14e-05	0.000763	CcSEcCtD
Cefdinir—Somnolence—Epirubicin—urinary bladder cancer	8e-05	0.00075	CcSEcCtD
Cefdinir—Anorexia—Doxorubicin—urinary bladder cancer	7.93e-05	0.000744	CcSEcCtD
Cefdinir—Dyspepsia—Epirubicin—urinary bladder cancer	7.92e-05	0.000743	CcSEcCtD
Cefdinir—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.86e-05	0.000737	CcSEcCtD
Cefdinir—Decreased appetite—Epirubicin—urinary bladder cancer	7.82e-05	0.000733	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	7.77e-05	0.000728	CcSEcCtD
Cefdinir—Constipation—Epirubicin—urinary bladder cancer	7.69e-05	0.000721	CcSEcCtD
Cefdinir—Abdominal pain—Methotrexate—urinary bladder cancer	7.6e-05	0.000713	CcSEcCtD
Cefdinir—Body temperature increased—Methotrexate—urinary bladder cancer	7.6e-05	0.000713	CcSEcCtD
Cefdinir—Insomnia—Doxorubicin—urinary bladder cancer	7.53e-05	0.000706	CcSEcCtD
Cefdinir—Somnolence—Doxorubicin—urinary bladder cancer	7.4e-05	0.000694	CcSEcCtD
Cefdinir—Gastrointestinal pain—Epirubicin—urinary bladder cancer	7.36e-05	0.00069	CcSEcCtD
Cefdinir—Dyspepsia—Doxorubicin—urinary bladder cancer	7.33e-05	0.000687	CcSEcCtD
Cefdinir—Decreased appetite—Doxorubicin—urinary bladder cancer	7.24e-05	0.000679	CcSEcCtD
Cefdinir—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	7.19e-05	0.000674	CcSEcCtD
Cefdinir—Constipation—Doxorubicin—urinary bladder cancer	7.12e-05	0.000668	CcSEcCtD
Cefdinir—Abdominal pain—Epirubicin—urinary bladder cancer	7.11e-05	0.000667	CcSEcCtD
Cefdinir—Body temperature increased—Epirubicin—urinary bladder cancer	7.11e-05	0.000667	CcSEcCtD
Cefdinir—Hypersensitivity—Methotrexate—urinary bladder cancer	7.08e-05	0.000664	CcSEcCtD
Cefdinir—Asthenia—Methotrexate—urinary bladder cancer	6.9e-05	0.000647	CcSEcCtD
Cefdinir—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.81e-05	0.000638	CcSEcCtD
Cefdinir—Pruritus—Methotrexate—urinary bladder cancer	6.8e-05	0.000638	CcSEcCtD
Cefdinir—Hypersensitivity—Epirubicin—urinary bladder cancer	6.63e-05	0.000622	CcSEcCtD
Cefdinir—Body temperature increased—Doxorubicin—urinary bladder cancer	6.58e-05	0.000617	CcSEcCtD
Cefdinir—Abdominal pain—Doxorubicin—urinary bladder cancer	6.58e-05	0.000617	CcSEcCtD
Cefdinir—Diarrhoea—Methotrexate—urinary bladder cancer	6.58e-05	0.000617	CcSEcCtD
Cefdinir—Asthenia—Epirubicin—urinary bladder cancer	6.45e-05	0.000605	CcSEcCtD
Cefdinir—Pruritus—Epirubicin—urinary bladder cancer	6.36e-05	0.000597	CcSEcCtD
Cefdinir—Dizziness—Methotrexate—urinary bladder cancer	6.36e-05	0.000596	CcSEcCtD
Cefdinir—Diarrhoea—Epirubicin—urinary bladder cancer	6.15e-05	0.000577	CcSEcCtD
Cefdinir—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.13e-05	0.000575	CcSEcCtD
Cefdinir—Vomiting—Methotrexate—urinary bladder cancer	6.11e-05	0.000573	CcSEcCtD
Cefdinir—Rash—Methotrexate—urinary bladder cancer	6.06e-05	0.000568	CcSEcCtD
Cefdinir—Dermatitis—Methotrexate—urinary bladder cancer	6.05e-05	0.000568	CcSEcCtD
Cefdinir—Headache—Methotrexate—urinary bladder cancer	6.02e-05	0.000565	CcSEcCtD
Cefdinir—Asthenia—Doxorubicin—urinary bladder cancer	5.97e-05	0.00056	CcSEcCtD
Cefdinir—Dizziness—Epirubicin—urinary bladder cancer	5.95e-05	0.000558	CcSEcCtD
Cefdinir—Pruritus—Doxorubicin—urinary bladder cancer	5.89e-05	0.000552	CcSEcCtD
Cefdinir—Vomiting—Epirubicin—urinary bladder cancer	5.72e-05	0.000536	CcSEcCtD
Cefdinir—Nausea—Methotrexate—urinary bladder cancer	5.71e-05	0.000536	CcSEcCtD
Cefdinir—Diarrhoea—Doxorubicin—urinary bladder cancer	5.69e-05	0.000534	CcSEcCtD
Cefdinir—Rash—Epirubicin—urinary bladder cancer	5.67e-05	0.000532	CcSEcCtD
Cefdinir—Dermatitis—Epirubicin—urinary bladder cancer	5.67e-05	0.000531	CcSEcCtD
Cefdinir—Headache—Epirubicin—urinary bladder cancer	5.64e-05	0.000529	CcSEcCtD
Cefdinir—Dizziness—Doxorubicin—urinary bladder cancer	5.5e-05	0.000516	CcSEcCtD
Cefdinir—Nausea—Epirubicin—urinary bladder cancer	5.34e-05	0.000501	CcSEcCtD
Cefdinir—Vomiting—Doxorubicin—urinary bladder cancer	5.29e-05	0.000496	CcSEcCtD
Cefdinir—Rash—Doxorubicin—urinary bladder cancer	5.25e-05	0.000492	CcSEcCtD
Cefdinir—Dermatitis—Doxorubicin—urinary bladder cancer	5.24e-05	0.000492	CcSEcCtD
Cefdinir—Headache—Doxorubicin—urinary bladder cancer	5.21e-05	0.000489	CcSEcCtD
Cefdinir—Nausea—Doxorubicin—urinary bladder cancer	4.94e-05	0.000464	CcSEcCtD
Cefdinir—Cefaclor—MPO—urinary bladder cancer	1.84e-05	1	CrCbGaD
